VICTORIA, BC, Nov. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB:
IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody
discovery and development, today announced that it has filed a
preliminary short form base shelf prospectus (the "Preliminary
Shelf Prospectus") with the securities commissions in each of
the provinces of Canada, excluding
Quebec, and a corresponding
registration statement on Form F-10 (the "Registration
Statement") with the United States Securities and Exchange
Commission (the "SEC") under the U.S./Canada
Multijurisdictional Disclosure System.
When made final or effective, the Preliminary Shelf Prospectus
and corresponding Registration Statement will allow the Company to
undertake offerings of common shares, preferred shares, debt
securities, warrants, units and subscription receipts
(collectively, the "Securities"), or any combination
thereof, up to an aggregate total of CAD$150
million from time to time during the 25-month period that
the final short form base shelf prospectus remains effective. The
Securities may be offered in amounts, at prices and on terms to be
determined at the time of sale and, subject to applicable
regulations, may include "at-the-market" transactions, public
offerings or strategic investments. The specific terms of any
offering of Securities, including the use of proceeds from any
offering, will be set forth in one or more shelf prospectus
supplement(s) to be filed with applicable securities
regulators.
A copy of the Preliminary Shelf Prospectus, and copies of the
final short form base shelf prospectus and any shelf prospectus
supplements that may be filed in the future, can be found under the
Company's SEDAR profile at www.sedar.com and on EDGAR at
www.sec.gov.
No securities regulatory authority has either approved or
disapproved the contents of this news release. The Registration
Statement filed today with the SEC has not yet become effective. No
Securities may be sold, nor may offers to buy be accepted, prior to
the time the Preliminary Shelf Prospectus and Registration
Statement become effective. This news release does not constitute
an offer to sell or a solicitation of an offer to buy any
securities of the Company in any jurisdiction in which such offer,
solicitation or sale would be unlawful.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with
end-to-end solutions empowering companies to discover and develop
therapies against any disease. The Company's experience and
cutting-edge technologies enable unparalleled support of its
partners in their quest to bring innovative treatments to the
clinic. ImmunoPrecise's full-service capabilities dramatically
reduce the time required for, and the inherent risk associated
with, conventional multi-vendor product development. For further
information, visit www.immunoprecise.com or contact
solutions@immunoprecise.com.
Forward-Looking Information and Statements
This press release contains certain "forward-looking
information" within the meaning of applicable Canadian securities
legislation. Such forward-looking information and forward-looking
statements are not representative of historical facts or
information or current condition but instead represent only the
Company's beliefs regarding future events, plans or objectives,
many of which, by their nature, are inherently uncertain and
outside of the Company's control. Generally, such forward-looking
information or forward-looking statements can be identified by the
use of forward-looking terminology such as "plans", "expects" or
"does not expect", "is expected", "budget", "scheduled",
"estimates", "forecasts", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or may contain statements that certain actions, events or results
"may", "could", "would", "might" or "will be taken", "will
continue", "will occur" or "will be achieved". Forward-looking
information contained in this press release includes information
relating to the (i) the filing and effectiveness of the final
base shelf prospectus and corresponding Registration Statement;
(ii) the filing and effectiveness of any potential prospectus
supplement; and (iii) the amount and terms of any Securities to be
offered.
By identifying such information and statements in this manner,
the Company is alerting the reader that such information and
statements are subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, level of
activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
information and statements.
Any such forward-looking statements are based on assumptions and
analyses made by the Company in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to the Company's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause the Company's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, the timing and filing of the
final base shelf prospectus and corresponding Registration
Statement; the potential offering of any Securities by the Company;
uncertainty with respect to the completion of any future offering;
the ability to obtain applicable regulatory approval for any
contemplated offerings; the ability of the Company to negotiate and
complete future funding transactions; and those risks and
uncertainties described in the Company's annual management
discussion and analysis for the previous quarter ended July 31, 2020 which can be accessed at
www.sedar.com. The forward-looking information and forward looking
statements contained in this press release are made as of the date
of this press release, and the Company does not undertake to update
any forward-looking information and/or forward-looking statements
that are contained or referenced herein, except in accordance with
applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accept responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.
